A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors
Status:
Not yet recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
This study is to assess the safety and tolerability, obtain Maximum Tolerated Dose (MTD)
and/or the recommended phase 2 dose (RP2D) of LM-101 as a single agent or in combination in
patients with advanced malignant tumors